Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Samelisant - Suven Life Sciences

Next Previous
X
Search
Drug Profile

Samelisant - Suven Life Sciences

Alternative Names: SUVN-G3031

Latest Information Update: 12 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suven Life Sciences
  • Class Acetamides; Antiparkinsonians; Cyclobutanes; Morpholines; Neuropsychotherapeutics; Nootropics; Phenyl ethers; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Histamine H3 receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Narcolepsy
  • No development reported Cognition disorders; Parkinson's disease

Most Recent Events

  • 13 Apr 2024 Efficacy and adverse events data from a phase II trial in Narcolepsy presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
  • 13 Jun 2023 Suven Life Sciences completes a phase II trial in Narcolepsy in USA, Canada (PO) (NCT04072380)
  • 21 Sep 2022 Suven Life Sciences completes an expanded-access programme for Narcolepsy (NCT05530447)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top